PVLA

Palvella Therapeutics, Inc.

Phase 2 AI-extracted

QTORIN™ rapamycin

Clinically Significant Angiokeratomas

Resolved

48days ago

Phase 2 readout · May 20, 2026

What's at stake Phase 2 trial results for QTORIN™ rapamycin in Clinically Significant Angiokeratomas are due May 20, 2026. A clean hit validates the program; a miss can gap the stock down hard.

Primary source · SEC 8-K verified 15h ago

“At Week 24, treatment with QTORIN™ rapamycin demonstrated a mean reduction of 1.43 points in cVM-MCSS Appearance score (n=14; p<0.001).”

Add to calendar Post on X Reddit

Provenance